Antitumor Activity of GSK1904529A, a Small-molecule Inhibitor of the Insulin-like Growth Factor-I Receptor Tyrosine Kinase
Peter Sabbatini(Jiangsu T-mab BioPharma (China)), Rakesh Kumar(The University of Texas MD Anderson Cancer Center)
Cited by 79
Related Papers
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
|Blood|2014|140
GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
|Molecular Cancer Therapeutics|2009|98
Identification of Pax5 as a Target of MTA1 in B-Cell Lymphomas
|Cancer Research|2007|68
Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A
|The Journal of Cell Biology|2010|59